Supplemental Material from JAAD Original Article Titled: Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6-months: a prospective analysis in the Corrona Psoriasis Registry

This data was collected from patients enrolled in CorEvitas’ Psoriasis Registry from April 2015 through June 2020. Supplemental Table 1: Proportion of patients achieving BSA≤1% and IGA0/1 by drug class and metabolic comorbid disease. Supplemental Table 2. Odds of achieving BSA≤1 and IGA0/1 by drug class and metabolic comorbid disease.本数据集采集自2015年4月至2020年6月期间，CorEvitas公司银屑病注册登记库（Psoriasis Registry）所纳入的患者。 补充表1：按药物类别与代谢共病分层，达到体表面积（Body Surface Area，BSA）≤1%且医师总体评估（Investigator's Global Assessment，IGA）等级为0/1的患者占比。 补充表2：按药物类别与代谢共病分层，达到体表面积≤1%且医师总体评估等级为0/1的优势比。